Bajaj Healthcare Limited has announced the sale of its undertaking to Bethany Pharmacare Private Limited through a regulatory disclosure filed on March 17, 2026. The transaction involves the disposal of the company's facility located at Plot No. L-9/3, MIDC, Tarapur, Taluka Boisar, District Palghar, Maharashtra.

Transaction Details

The company has signed a Deed of Assignment and Transfer with Bethany Pharmacare Private Limited for the sale of the undertaking. The key parameters of this transaction are outlined below:

Operational and Financial Impact

The undertaking being sold was not operational during the last financial year, resulting in nil contribution to the company's turnover or revenue. This indicates that the disposal involves a non-productive asset that was not generating income for Bajaj Healthcare Limited.

The transaction is expected to be completed upon fulfillment of conditions mentioned in the Deed of Assignment and Transfer, though no specific completion timeline has been disclosed.

Regulatory Compliance

Bajaj Healthcare Limited has confirmed several important aspects regarding the transaction's compliance:

Prior Approvals and Governance

The company had proactively obtained shareholder approval for this disposal through a postal ballot process. The approval was secured on August 05, 2023, via postal ballot notice dated June 28, 2023. This demonstrates the company's adherence to proper governance procedures and compliance with SEBI LODR Regulation 37A requirements.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders regarding this material corporate action.

Bajaj Healthcare Limited has announced the successful completion of its postal ballot voting process, with all seven special resolutions receiving approval from shareholders. The remote e-voting concluded on February 19, 2026 at 5.00 pm (IST), with results submitted to stock exchanges in compliance with SEBI regulations.

Postal Ballot Overview

The postal ballot was conducted entirely through electronic voting via NSDL's platform, spanning from January 20, 2026 at 9.00 am (IST) to February 19, 2026 at 5.00 pm (IST). The company had 38426 shareholders eligible to vote as of the record date of January 16, 2026.

Resolution Results

All seven special resolutions were passed with overwhelming shareholder support. The resolutions covered key board appointments and re-appointments of senior management positions.

New Independent Director Appointments

Three new independent directors were appointed to strengthen the board:

Management Re-appointments

Four key management personnel were re-appointed to their respective positions:

Voting Participation Analysis

The voting showed strong participation from promoter groups and institutional investors:

Promoter and Promoter Group:

• Shares held: 18695042
• Voting participation: 100.0000%
• Unanimous support for all resolutions

Public Institutions:

• Shares held: 1303474
• Voting participation: 46.0205%
• Strong support across all resolutions

Public Non-Institutions:

• Shares held: 11584736
• Voting participation: 0.1033%
• Mixed but generally supportive voting pattern

Regulatory Compliance

The postal ballot process was conducted in full compliance with Section 108 of the Companies Act, 2013 and SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Mr. Haresh Sanghvi, a practicing Company Secretary (FCS 2259), served as the scrutinizer and submitted his detailed report confirming the fairness and transparency of the e-voting process.

The voting results and scrutinizer's report have been made available on the company's website at https://www.bajajhealth.com/ and NSDL's website at www.evoting.nsdl.com , ensuring complete transparency for all stakeholders.